Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type I response in vitro:: mechanisms for viral immune escape

被引:102
作者
Beckebaum, S [1 ]
Cicinnati, VR
Zhang, X
Ferencik, S
Frilling, A
Grosse-Wilde, H
Broelsch, CE
Gerken, G
机构
[1] Univ Essen Gesamthsch, Dept Gastroenterol & Hepatol, OPZ 2, LTX Ambulanz, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Dept Gen Surg & Transplantat, D-45122 Essen, Germany
[3] Univ Essen Gesamthsch, Inst Immunol, D-45122 Essen, Germany
关键词
D O I
10.1046/j.1365-2567.2003.01699.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dendritic cells (DC) are the most potent antigen-presenting cells and play a central role in the induction of antiviral immune responses. Recently, we have shown that monocyte-derived DC (MoDC) from patients with chronic hepatitis B virus (HBV) infection are functionally impaired. In our present study MoDC from healthy subjects were propagated in vitro and inoculated with HBV particles to investigate the precise mechanisms that underly MoDC dysfunction. T-cell proliferation assays revealed an impaired allostimulatory capacity of HBV-inoculated MoDC (HBV-MoDC) as well as a lower potential of stimulating autologous T cells against a recall antigen in comparison to control-MoDC. Interleukin-2, turnout necrosis factor-alpha and interferon-gamma production by T cells in proliferation assays with HBV-MoDC was significantly lower than with control-MoDC and correlated with lower IL-12 production in HBV-MoDC cultures. The presence of the nucleoside analogue lamivudine (3TC), an inhibitor of HBV replication, restored impaired allostimulatory function of HBV-MoDC and up-regulated major histocompatibility complex class II expression. These results show that HBV infection compromises the antigen-presenting function of MoDC with concomitant impairment of T helper cell type 1 responses. This may play an important role for viral immune escape leading to chronic HBV infection. However, 3TC treatment can overcome HBV-MoDC-related T-cell hyporeactivity and this underscores its important role in enhanced immune responses to HBV.
引用
收藏
页码:487 / 495
页数:9
相关论文
共 50 条
  • [1] HLA AND HEPATITIS-B INFECTION
    ALMARRI, A
    BATCHELOR, JR
    [J]. LANCET, 1994, 344 (8931) : 1194 - 1195
  • [2] Antonaci S, 2001, MICROBIOS, V106, P203
  • [3] Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection
    Auffermann-Gratzinger, S
    Keeffe, EB
    Levy, S
    [J]. BLOOD, 2001, 97 (10) : 3171 - 3176
  • [4] Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection
    Beckebaum, S
    Cicinnati, VR
    Dworacki, G
    Müller-Berghaus, J
    Stolz, D
    Harnaha, J
    Whiteside, TL
    Thomson, AW
    Lu, L
    Fung, JJ
    Bonham, CA
    [J]. CLINICAL IMMUNOLOGY, 2002, 104 (02) : 138 - 150
  • [5] NATURAL VARIANTS OF CYTOTOXIC EPITOPES ARE T-CELL RECEPTOR ANTAGONISTS FOR ANTIVIRAL CYTOTOXIC T-CELLS
    BERTOLETTI, A
    SETTE, A
    CHISARI, FV
    PENNA, A
    LEVRERO, M
    DECARLI, M
    FIACCADORI, F
    FERRARI, C
    [J]. NATURE, 1994, 369 (6479) : 407 - 410
  • [6] Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
    Boni, C
    Bertoletti, A
    Penna, A
    Cavalli, A
    Pilli, M
    Urbani, S
    Scognamiglio, P
    Boehme, R
    Panebianco, R
    Fiaccadori, F
    Ferrari, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) : 968 - 975
  • [7] (-)-2'-DEOXY-3'-THIACYTIDINE IS A POTENT, HIGHLY SELECTIVE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2 REPLICATION INVITRO
    COATES, JAV
    CAMMACK, N
    JENKINSON, HJ
    JOWETT, AJ
    JOWETT, MI
    PEARSON, BA
    PENN, CR
    ROUSE, PL
    VINER, KC
    CAMERON, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) : 733 - 739
  • [8] In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
    Colledge, D
    Civitico, G
    Locarnini, S
    Shaw, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 551 - 560
  • [9] Engelmayer J, 1999, J IMMUNOL, V163, P6762
  • [10] FERRARI C, 1990, J IMMUNOL, V145, P3442